文献速递心脑血管急症消化、代谢与肾脏急症

2024-2025年COVID-19疫苗与美国退伍军人主要不良心血管事件

2024-2025 COVID-19 Vaccine and Major Adverse Cardiovascular Events Among US Veterans.
PubMed 文献 · JAMA Intern Med · 2026-01-01
一句话结论在退伍军人队列中,2024-2025年COVID-19疫苗与流感疫苗同期接种相比单独接种流感疫苗,8个月时COVID-19相关主要不良心血管事件风险降低37.7%,75岁以上人群获益最明显。

该研究采用目标试验模拟的队列设计,利用美国退伍军人事务部电子健康记录,纳入2024年9月3日至12月31日期间接种疫苗的退伍军人。比较同日接种2024-2025年COVID-19疫苗和流感疫苗与仅接种流感疫苗者,主要终点为COVID-19相关主要不良心血管事件复合终点。8个月时,接种COVID-19疫苗者COVID-19相关主要不良心血管事件风险降低37.7%(95%CI 18.2%-54.9%),每万人风险差2.0(95%CI 0.9-3.7)。疫苗有效性仅在75岁以上人群中具有统计学显著性(VE 50.7%,95%CI 31.8%-65.6%),该人群绝对风险降低最大(每万人减少5.5例事件)。65岁以下及65-75岁人群中未观察到统计学显著的疫苗有效性。

要点

  • 在75岁以上退伍军人中,2024-2025年COVID-19疫苗与流感疫苗同期接种相比单独接种流感疫苗,8个月时COVID-19相关主要不良心血管事件疫苗有效性为50.7%(95%CI 31.8%-65.6%),每万人减少5.5例事件。
  • 65岁以下和65-75岁人群中,COVID-19相关主要不良心血管事件的疫苗有效性未达统计学显著。
  • 在有合并症和无合并症的亚组中,COVID-19相关主要不良心血管事件的相对疫苗有效性均具有统计学显著性,但有合并症者的绝对获益持续且显著更大。
  • 全因主要不良心血管事件的风险差为每万人23.7(95%CI 14.1-34.7),绝对风险降低幅度明显大于COVID-19相关主要不良心血管事件。
  • 总体人群中,COVID-19相关主要不良心血管事件的疫苗有效性为37.7%(95%CI 18.2%-54.9%),每万人风险差2.0(95%CI 0.9-3.7)。

适用人群与场景

  • 美国退伍军人事务部电子健康记录中,2024年9月3日至2024年12月31日期间有疫苗接种记录的退伍军人。
  • 纳入分析者均接种了流感疫苗,其中同日接种2024-2025年COVID-19疫苗者349 085人,未接种COVID-19疫苗者690 574人。
  • 平均(标准差)年龄70.1(12.4)岁,男性954 341人(91.8%)。

研究设计与关键结果

  • 研究设计为目标试验模拟的队列研究,使用美国退伍军人事务部电子健康记录,比较同日接种2024-2025年COVID-19疫苗和流感疫苗与仅接种流感疫苗。
  • 共纳入1 039 659名参与者,其中349 085人接种COVID-19疫苗,690 574人未接种。
  • 主要终点为COVID-19相关主要不良心血管事件复合终点,定义为COVID-19相关心血管死亡、心肌梗死、卒中或心力衰竭住院。
  • 8个月时,COVID-19疫苗与较低的COVID-19相关主要不良心血管事件风险相关(疫苗有效性37.7%[95%CI 18.2%-54.9%];每万人风险差2.0[95%CI 0.9-3.7])。
  • COVID-19相关主要不良心血管事件的疫苗有效性仅在75岁以上人群中具有统计学显著性(疫苗有效性50.7%[95%CI 31.8%-65.6%]),该人群绝对风险降低最大(每万人减少5.5例事件)。
  • 65岁以下和65-75岁人群中未观察到统计学显著的疫苗有效性。
  • 在有合并症和无合并症的亚组中,COVID-19相关主要不良心血管事件的相对疫苗有效性均具有统计学显著性,但有合并症者的绝对获益持续且显著更大。
  • 次要分析显示全因主要不良心血管事件、全因住院和全因死亡的绝对风险降低幅度更大(全因主要不良心血管事件风险差每万人23.7[95%CI 14.1-34.7])。

证据类型、等级与局限

  • 证据类型:目标试验模拟的队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,接种2024-2025年COVID-19疫苗与COVID-19相关主要不良心血管事件风险降低相关,在75岁以上和有合并症人群中降低最明显。
  • 作者认为,虽然COVID-19相关主要不良心血管事件的降低幅度不大,但全因主要不良心血管事件的大幅降低提示疫苗的保护关联延伸至未检测的SARS-CoV-2及其后遗症的隐藏负担。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: COVID-19 vaccines were previously shown to reduce risk of major adverse cardiovascular events (MACEs). Whether the 2024-2025 COVID-19 vaccine continues to reduce COVID-19-associated MACEs in the context of evolving variants and widespread population immunity is unknown.

OBJECTIVE: To determine whether the 2024-2025 COVID-19 vaccine is associated with reduced risk of COVID-19-associated MACE.

DESIGN, SETTING, AND PARTICIPANTS: This cohort study was a target-trial emulation using US Department of Veterans Affairs (VA) electronic health records. Participants were veterans with vaccination encounters between September 3, 2024, and December 31, 2024.

EXPOSURES: Same-day coadministration of the 2024-2025 COVID-19 and influenza vaccines vs influenza vaccine alone.

MAIN OUTCOMES AND MEASURES: Composite end point of COVID-19-associated MACE, defined as COVID-19-associated cardiovascular death, myocardial infarction, stroke, or hospitalization for heart failure. Secondary outcomes included all-cause MACE, hospitalization, and death. Vaccine effectiveness (VE), calculated as 1 minus the risk ratio, and risk difference were estimated at 8 months using inverse probability weighting.

RESULTS: Among 1 039 659 participants who received influenza vaccine (mean [SD] age, 70.1 [12.4] years; 954 341 [91.8%] men), 349 085 received COVID-19 vaccine and 690 574 did not. At 8 months, the COVID-19 vaccine was associated with lower risk of COVID-19-associated MACE (VE, 37.7% [95% CI, 18.2%-54.9%]; risk difference per 10 000 persons, 2.0 [95% CI, 0.9-3.7]). VE for COVID-19-associated MACE was statistically significant only in individuals older than 75 years (VE, 50.7% [95% CI, 31.8%-65.6%]), a group that also experienced the largest absolute risk reduction (5.5 fewer events per 10 000 individuals). No statistically significant vaccine effectiveness was observed among those younger than 65 years or aged 65 to 75 years. While VE for COVID-19-associated MACE on the relative scale was statistically significant across subgroups of participants with and without comorbid health conditions, the absolute benefit was consistently and substantially greater for individuals with the comorbid health condition. Secondary analyses of all-cause MACE, all-cause hospitalization, and all-cause death suggested substantially larger absolute risk reductions (risk difference for all-cause MACE, 23.7 [95% CI, 14.1 to 34.7]).

CONCLUSIONS AND RELEVANCE: In this cohort study, receipt of the 2024-2025 COVID-19 vaccine was associated with reduced risk of COVID-19-associated MACE, with reductions most prominent in those 75 years or older and those with comorbidities. While the reduction in COVID-19-associated MACE was modest, the substantially larger reduction in all-cause MACE suggests that the vaccine's protective association extends to the hidden burden of undetected SARS-CoV-2 and its sequelae.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Cai M, Xie Y, Al-Aly Z, et al. 2024-2025 COVID-19 Vaccine and Major Adverse Cardiovascular Events Among US Veterans. JAMA Intern Med. 2026. PMID: 42295793. doi:10.1001/jamainternmed.2026.1929

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。